Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mylan agrees to buy Famy Care Businesses
The acquisition will build on Mylan’s existing partnerships with Famy Care in North America, Europe and Australia, and provide Mylan with an enhanced and now vertically integrated platform
The acquisition will build on Mylan’s existing partnerships with Famy Care in North America, Europe and Australia, and provide Mylan with an enhanced and now vertically integrated platform
These are in addition to multiple other patents that have been issued and granted in the United States, Mexico and Australia for ophthalmic administration of voclosporin. Further patent
The cell bank contains over 2.6 billion human cells, sufficient to meet the company’s foreseeable clinical trial requirements. "Completing the production of clinical-grade cells using the previously published
Following a meeting with its CBD Initiative Scientific/Medical Advisory Board last November, the company has marked significant progress in readying its first natural CBD-based nutraceutical supplement for introduction
NEPA is an oral fixed combination of a novel NK1receptor antagonist (netupitant) and the best-in-class 5-HT3receptor antagonist palonosetron, already approved in the USA with the trade name AKYNZEO
This decision result ed from a vaccine portfolio prioritization process to ensure that Takeda’s R&D resource s are directed toward the highest – impact programs for public health.
The agreement grants Nicox exclusive rights to commercialize all three products in Europe (including Eastern Europe), Middle East and Africa (EMEA). Nicox expects to file European Marketing Authorizations
Self-administered subcutaneously, Hizentra delivers consistent levels of immunoglobulin G (IgG) regardless of dosing schedule. Hizentra, the first and only 20 percent subcutaneous immunoglobulin, received FDA approval in March
This study is the first of a number of preclinical studies that will be performed. These studies are designed to test the safety, efficacy and dosing of Melligen
As of this date, Amherst has not paid or entered into an agreement to pay the FDA the amount owed. Under the terms of our agreement with Amherst,